Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
314.7 USD | -1.35% | +0.59% | +9.27% |
Kurzporträt
- Arzneimittelverkäufe (94,2%): Medikamente zur Behandlung von Krebs, Stoffwechselstörungen, Knochenerkrankungen, Nierenversagen, Hämophilie usw.;
- Sonstige (5,8%): hauptsächlich Lizenzeinnahmen.
Auf die Vereinigten Staaten entfallen 70,3% des Nettoumsatzes.
Mitarbeiterzahl: 26 700
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8.50% |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15.90% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6.51% |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8.91% |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35.62% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01.06.06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23.10.19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18.12. |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01.01.07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01.01.15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01.01.05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01.08.18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.06.23 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03.02.17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14.10.16 |
Robert Williams
BRD | Director/Board Member | 75 | 17.10.14 |
Robert Eckert
BRD | Director/Board Member | 69 | 01.01.03 |
Ronald Sugar
BRD | Director/Board Member | 75 | 22.07.10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01.06.06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24.10.17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01.01.12 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30.07.21 |
Greg Garland
BRD | Director/Board Member | 66 | 16.10.13 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 536 434 692 | 535 107 021 ( 99,75 %) | 0 | 99,75 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
BEIGENE, LTD. 19,80% | 246 269 426 | 19,80% | 2 978 709 976 $ |
NEUMORA THERAPEUTICS, INC. 22,26% | 35 368 653 | 22,26% | 320 439 996 $ |
4 910 000 | 5,50% | 105 270 400 $ | |
VIGIL NEUROSCIENCE, INC. 8,53% | 3 206 281 | 8,53% | 8 272 205 $ |
100 993 | 0,67% | 2 139 032 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Amgen Manufacturing Ltd. (Bermuda)
| |
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The company is located in Bermuda. |
Biotechnology
|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+9.27% | 169 Mrd. | |
+32.36% | 694 Mrd. | |
+30.02% | 593 Mrd. | |
-1.60% | 371 Mrd. | |
+20.07% | 331 Mrd. | |
+6.04% | 290 Mrd. | |
+14.35% | 239 Mrd. | |
+10.36% | 209 Mrd. | |
-3.23% | 209 Mrd. | |
+0.45% | 164 Mrd. |
- Börse
- Aktien
- 867900 Aktie
- Unternehmen Amgen Inc.